As of Friday close, Nutex Health Inc.’s (NASDAQ:NUTX) stock traded at $0.20. The average number of shares traded per day over the past five days has been 2,635,360 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0249 fall in that time frame. In the last twenty days, the average volume was 3,166,680, while in the previous 50 days, it was 2,137,128.
Since last month, NUTX stock retreated -33.73%. Shares of the company fell to $0.1852 on 09/22/23, the lowest level in the past month. A 52-week high of $2.46 was reached on 01/04/23 after having rallying from a 52-week low of $0.19. Since the beginning of this year, NUTX’s stock price has dropped by -89.54% or -$1.7012, and marked a new high 2 times. However, the stock has declined by -91.92% since its 52-week high.
NUTX stock investors should be aware that Nutex Health Inc. (NUTX) stock had its last reported insider trading activity 23 days ago on Aug 31. Vo Thomas T., the Chief Executive Officer of the company, purchased of 152,326 shares for $0.28 on Aug 31. It resulted in a $42,651 investment by the insider. Vo Thomas T. added 305,947 shares at an average price of $0.31 on Aug 30. The insider now owns 269,170,450 shares following the transaction. On Aug 29, Chief Executive Officer Vo Thomas T. bought 342,744 shares at $0.30 apiece. The transaction was valued at $102,823.
Valuation Metrics
The stock’s beta is 0.76. Besides these, the trailing price-to-sales (P/S) ratio of 0.63, the price-to-book (PB) ratio of 1.42.
Financial Health
In the three months ended June 29, Nutex Health Inc.’s quick ratio stood at 1.60, while its current ratio was 1.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 2.65, and the total debt-to-equity ratio was 2.91. On the profitability front, the trailing twelve-month gross margin is -5.80% percent. Based on annual data, NUTX earned $13.45 million in gross profit and brought in $219.29 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -122.70%. Return on equity (ROE) for the past 12 months was -444.90%.
In Nutex Health Inc.’s quarter-end financial report for June 29, it reported total debt of $25.11 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. NUTX’s revenue rose 1.48% to $56.33 million during the quarter, while net income inched up to $58.92 million. While analysts expected Nutex Health Inc. to report $0 quarterly earnings, the actual figure was -$0.01 per share. During the quarter, the company generated $3.8 million in EBITDA. The liabilities of Nutex Health Inc. were 328.01 million at the end of its most recent quarter ended June 29, and its total debt was $286.89 million. The value of shareholders’ equity is $661.9 million.
Technical Picture
This quick technical analysis looks at Nutex Health Inc.’s (NUTX) price momentum. With a historical volatility rate of 109.78%, the RSI 9-day stood at 29.91% on 22 September.
With respect to its five-day moving average, the current Nutex Health Inc. price is down by -11.13% percent or -$0.0249. At present, NUTX shares trade -28.49% below its 20-day simple moving average and -62.81% percent below its 100-day simple moving average. However, the stock is currently trading approximately -51.29% below its SMA50 and -89.48% below its SMA200.
Stochastic coefficient K was 7.22% and Stochastic coefficient D was 8.18%, while ATR was 0.0251. Given the Stochastic reading of 11.85% for the 14-day period, the RSI (14) reading has been calculated as 32.14%. As of today, the MACD Oscillator reading stands at -0.0113, while the 14-day reading stands at -0.0327.
Analyst Ratings
Northland Capital launched its rating on Nutex Health Inc. (NASDAQ: NUTX) to an Outperform in a note to investors on February 22, 2023. Nutex Health Inc. (NUTX) has been rated Buy by analysts. According to 0 brokerage firms, NUTX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Nutex Health Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $2.38, the current consensus forecast for the stock is $2.25 – $2.50. Based on these forecasts, analysts predict Nutex Health Inc. (NUTX) will achieve an average price target of $2.38.
